ObjectiveTo evaluate the height and weight development of children with congenital heart
disease undergoing surgery with the goal of determining when they reach the
threshold of normal development and whether there are differences between patients
with developmental pattern below the level of normality preoperatively
(z-score<-2 for the analyzed parameter) in comparison to the total group of
cardiac patients.MethodsWe prospectively followed up 27 children undergoing operation into five time
periods: preoperatively and at four subsequent outpatient appointments:
1st month, 3rd month, 6th month and
12th month after hospital discharge. The anthropometric parameters
used were median z-score (MZ), weight (WAZ), height (HAZ), subscapular skinfold
(SSFAZ), upper arm circumference (UAC) and triceps skinfold (TSFAZ). The evolution
assessment of the parameters was performed by analysis of variance and comparison
with the general normal population from unpaired t test, both in the total group
of cardiac patients, and in subgroups with preoperative parameters below the
normal level (Zm<-2).ResultsIn the total group there was no significant evolution of MZ of all parameters. WAZ
was statistically lower than the normal population until the 1st month
of follow-up (P=0.028); HAZ only preoperatively
(P=0.044), SSFAZ in the first month (P=0.015)
and at 12th month (P=0.038), UAC and TSFAZ were always
statistically equal to the general population. In patients whose development was
below the level of normality, there were important variation of WAZ
(P=0.002), HAZ (P=0.001) and UAC
(P=0.031) after the operation, and the WAZ was lower than the
normal population until the 3rd month (P=0.015); HAZ
and UAC, until the first month (P=0.024 and
P=0.039 respectively), SSFAZ, up to the 12th month
(P=0.005), the TSFAZ only preoperatively
(P=0.011).ConclusionThe operation promoted the return to normalcy for those with heart disease in
general within up to three months, but for the group of patients below normal
developmental pattern of the return occurred within 12 months.
IntroductionLeft atrioventricular valve regurgitation is the most concerning residual lesion
after surgical correction of atrioventricular septal defects.ObjectiveTo determine factors associated with moderate or severe left atrioventricular
valve regurgitation within 30 days of surgical repair of complete atrioventricular
septal defect.MethodsWe assessed the results of 53 consecutive patients 3 years-old and younger
presenting with complete atrioventricular septal defect that were operated on at
our practice between 2002 and 2010. The following variables were considered: age,
weight, absence of Down syndrome, grade of preoperative atrioventricular valve
regurgitation, abnormalities on the left atrioventricular valve and the use of
annuloplasty. Median age was 6.7 months; median weight was 5.3 Kg; 86.8% had Down
syndrome. At the time of preoperative evaluation, there were 26 cases with
moderate or severe left atrioventricular valve regurgitation (49.1%).
Abnormalities on the left atrioventricular valve were found in 11.3%; annuloplasty
was performed in 34% of the patients.ResultsAt the time of postoperative evaluation, there were 21 cases with moderate or
severe left atrioventricular valve regurgitation (39.6%). After performing a
multivariate analysis, the only significant factor associated with moderate or
severe left atrioventricular valve regurgitation was the absence of Down syndrome
(P=0.03).ConclusionAbsence of Down syndrome was associated with moderate or severe postoperative left
atrioventricular valve regurgitation after surgical repair of complete
atrioventricular septal defect at our practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.